問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間:2023-09-19

羅淑芬Lo, Shue-Fen
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years
  • lsf00076@cgmh.org.tw

篩選

List

92Cases

2014-07-31 - 2017-03-30

Others

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis
  • Condition/Disease

    Severely Active Rheumatoid Arthritis

  • Test Drug

    Tofacitinib (Xeljanz)

Participate Sites
6Sites

Terminated6Sites

2014-03-14 - 2020-07-22

Phase IV

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
  • Condition/Disease

    rheumatoid arthritis

  • Test Drug

    Xeljanz

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites